Market Summary | Major Indices | Market Movers | Market Sectors | Mutual Funds | A-Z Stock Listings
ETF Screener | World Markets | Currencies | CEO Wealthmeter | Oil / Energy | Metals
Treasury Rates | Calculators | My Watchlist | My Portfolio
         Symbol Lookup
REPLIGEN Add to My Watchlist (NSDQ: RGEN) 
Detailed Quote
News
Chart
SEC Filings
Profile
Historical
Options
     Repligen Corp 3.36 -0.04 (-1.18%) 40,180
41 Seyon Street
Building #1, Suite 100
Waltham, MA 02453 US
(781) 250-0111
(781) 250-0115 fax
www.repligen.com
CEO Dr. Walter C. Herlihy, Ph.D.
Auditor Ernst & Young LLP
Exchange Traded NQ
ISIN Number US7599161095
CIK Number 730272
NAICS Code 325414
Business Summary
A biopharmaceutical company, focused primarily on the development of novel therapeutics for radiology and neuropsychiatry.
Number of Employees 69
Share Fundamentals
Market Cap 103.36M
Shares Outstanding 30.76M
Float 20.51M
Short Interest 791.71K
Financial Strength
Revenue (TTM) $21,093,192
Earnings (TTM) -$4,760,321
Quick Ratio 11.9:1
Current Ratio 12.6:1
Total Debt/Equity 0:1
Profitability
Gross Margin 77.2%
EBITDA Margin -24.5%
Profit Margin -23.7%
Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Investing News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs